You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ERGOLOID MESYLATES

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ergoloid mesylates

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01475578 ↗	Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)	Completed	Sinphar Pharmaceutical Co., Ltd	Phase 2	2002-03-01	The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed.
NCT05030129 ↗	Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome	Not yet recruiting	Elizabeth Berry-Kravis	Phase 2	2021-09-15	A preliminary assessment of the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ergoloid mesylates

Condition Name

Chart
Table

Condition Name for ergoloid mesylates
Intervention	Trials
Fragile X Syndrome	1
Vascular Dementia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ergoloid mesylates
Intervention	Trials
Syndrome	1
Fragile X Syndrome	1
Dementia, Vascular	1
Dementia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ergoloid mesylates

Trials by Country

Map
Table

Trials by Country for ergoloid mesylates
Location	Trials
China	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ergoloid mesylates

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ergoloid mesylates
Clinical Trial Phase	Trials
Phase 2	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ergoloid mesylates
Clinical Trial Phase	Trials
Not yet recruiting	1
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ergoloid mesylates

Sponsor Name

Chart
Table

Sponsor Name for ergoloid mesylates
Sponsor	Trials
Sinphar Pharmaceutical Co., Ltd	1
Elizabeth Berry-Kravis	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ergoloid mesylates
Sponsor	Trials
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.